Emerging Therapies Plaque Psoriasis

Long-term data support tildrakizumab safety, user-friendliness
August 24, 2020

Phase 3 data show tildrakizumab’s (Ilumya, Sun Pharma) efficacy and safety last up to five years.

Meta-analysis reaffirms safety, efficacy of intermittent biologic use
August 24, 2020

According to a recent meta-analysis, patients who stop and restart biologic treatment can regain psoriasis control without experiencing unexpected safety issues.

Autoantigen array identifies IgG4 anti-gliadin autoantibody
August 18, 2020

Using a novel autoantigen array, researchers have shown that the IgG4 anti-gliadin autoantibody might provide useful information for diagnosis and prognosis of psoriasis.

Calcipotriene betamethasone foam phase 3 trial succeeds
July 27, 2020

Twice-weekly treatment with calcipotriene-betamethasone diproprionate provides safe and effective maintenance treatment for plaque psoriasis, according to phase 3 data.

Therapeutic, management considerations with biologics
July 24, 2020

Studies offer further insight into risks associated with biologic therapy. One study suggests it’s not necessary to stop biologic therapy preoperatively to limit post-operative infections. Another systematic review does not rule out melanoma risk.

Bimekizumab phase 3 data reflect rapid, durable response
June 29, 2020

Phase 3 data announced at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020 demonstrate that the second-generation IL-17 inhibitor may offer long-lasting, safe treatment for patients with psoriasis.

Biologics enter post-PASI era
June 26, 2020

With newer biologics consistently posting PASI improvements greater than 90%, dermatologists need to consider other factors when selecting a treatment. However, nuanced differences between the same drug class could be teased out, one expert says.

Ixekizumab offers quick, lasting relief for genital psoriasis
June 19, 2020

A recent study shows ixekizumab may be able to help treat moderate-to-severe cases of genital psoriasis.

Oral apremilast effectively treats scalp psoriasis
June 19, 2020

A recent article shows oral apremilast may rapidly and significantly improve moderate-to-severe scalp psoriasis.